171 results
Page 2 of 9
8-K
go89w
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
hc7joze86rbas
22 May 23
Business combination disclosure
7:01am
8-K
7wa 8wvao
22 May 23
Other Events
6:59am
8-K
EX-99.1
9qwmb 8m4nc
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
zf1cvym0j44xntq2r
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
soesqzdgarq
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
8-K
EX-10.1
s4n9v1nte6911wqnfcqx
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
8-K
EX-99.1
gkf9ikw
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
S-4
k07ctlph6q egw
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-99.1
ck9o8jm1b0khetkeg
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
392hvkwg
8 Nov 22
Regulation FD Disclosure
7:40am
8-K
EX-99.1
s5now6mif fv
25 Oct 22
Adaptimmune Enhances its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK
8:10am
8-K
EX-99.1
pf0qdh0hetnmz
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am
8-K
EX-99.1
jp9052
4 Aug 22
Adaptimmune Reports Second-Quarter Financial Results and Business Update
7:36am